Seamless transition! Keyuan Pharmaceutical appoints new leadership team, with growth strategy remaining unchanged?

Listing | Zhongfang Network

Review | Li Xiaoyan

On March 13, Keyuan Pharmaceutical (301281.SZ) announced that President Gao Chunpo resigned from his positions as President and Legal Representative due to “work adjustments,” and will no longer hold any positions within the company after stepping down. On the same day, the company swiftly completed the appointment of new management: Wei Zhiguo was appointed as the new President, and Li Yanbing as Vice President and Chief Financial Officer, both with terms until the expiration of the fourth Board of Directors. This smooth transition, characterized by “resignation and immediate appointment,” marks the company’s official entry into a new operational management cycle, anchoring a new direction focused on quality improvement, efficiency, and breaking through growth barriers amid industry transformation.

The neutral wording of “work adjustments” in the announcement, combined with the statement that Gao Chunpo will not hold any positions after stepping down, conveys a rational and efficient management change at Keyuan Pharmaceutical. During his tenure, Gao Chunpo led the company in product layout, market expansion, and governance standardization, achieving phased results and laying a solid foundation for future development. The company expressed gratitude for his diligent service and contributions, reflecting respect for past efforts and a sense of continuity.

The key highlight of this transition is seamless integration. The new management team holds core positions: Wei Zhiguo oversees overall operations, while Li Yanbing manages finance and internal controls. Their clear division of responsibilities and complementary strengths quickly form a new operational synergy. This arrangement ensures business continuity and provides dual support for strategy implementation and risk management, demonstrating the maturity of the company’s governance.

Wei Zhiguo, born in 1979, holds a bachelor’s degree and an EMBA master’s degree, with a registered safety engineer qualification. His career spans management roles across the pharmaceutical industry chain. He has served as President of Shanghai Huatuo Pharmaceutical, Assistant to the Chairman of Beijing Beilu Pharmaceutical, and head of operations at Sichuan Huiyu Pharmaceutical. Before joining Keyuan Pharmaceutical, he was President of Shandong Linuo Pharmaceutical.

From his background, Wei Zhiguo is a typical management executive with both strategic vision and execution capability. His experience in multiple pharmaceutical companies covers production operations, team management, and market expansion, with expertise in optimizing management and boosting performance during industry cycles. His external appointment, rather than internal promotion, brings outside industry resources and advanced management experience to Keyuan Pharmaceutical, potentially injecting new growth momentum.

Alongside Wei Zhiguo, Li Yanbing, born in 1982, holds a master’s degree in accounting from Renmin University of China and is a CMA (Certified Management Accountant). She previously served as CFO at Yiling Wanzhou International Pharmaceutical. With extensive experience in pharmaceutical financial management, she possesses solid skills in financial planning, cost control, and risk mitigation.

Promoting the financial head to Vice President signals a focus on strengthening financial control and improving operational quality. Li Yanbing’s addition will help establish a more rigorous internal control system, more efficient capital management, and provide data-driven insights for decision-making. This will support the company in maintaining profitability and optimizing asset quality amid normalized procurement and intensified industry competition.

Currently, Keyuan Pharmaceutical is in a growth stage, with a scale still below industry leaders but with a solid fundamental foundation. In the first three quarters of 2025, the company achieved operating revenue of 303 million yuan and net profit attributable to shareholders of 31.47 million yuan, with an overall profit margin of about 10%. Its performance in specialty chemicals and raw materials remains at a reasonable level. As of the end of Q3, total assets stood at 1.606 billion yuan, shareholders’ equity at 1.371 billion yuan, and cash flow was healthy, with net cash flow from operating activities of 27.24 million yuan, up 14.11% year-over-year, demonstrating strong “cash-generating capacity.”

In the short term, the company faces industry-wide challenges: net profit attributable to shareholders in 2025 is expected to decline by 70%-80% year-over-year, mainly due to factors such as expansion in formulation markets and litigation expenses of subsidiaries. However, this is not a decline in core competitiveness but a phase of industry adjustment and pain. The company is actively responding, with R&D expenses in the first three quarters increasing by 58.75% to 35.49 million yuan, investing more in innovation and market expansion to build long-term momentum.

In the face of industry transformation, the new leadership team of Wei Zhiguo and Li Yanbing needs to focus precisely on stabilizing the fundamentals and seeking new growth. The core tasks are concentrated in three areas:

1. Optimize product structure to strengthen core competitiveness. Keyuan Pharmaceutical should focus on its advantageous products, increase R&D investment and evidence-based research, and improve product quality and brand influence. Simultaneously, it should optimize capacity layout, promote strategies like “opening markets in the off-season and supplying in the peak season,” and reduce costs through scale production to resist competitive pressures in the stock industry.

2. Strengthen financial control to improve operational quality. Relying on Li Yanbing’s expertise, the company will further streamline accounts receivable, control inventory risks, and establish a refined capital management system. By empowering finance to optimize business processes and improve expense efficiency, the company aims to drive revenue growth and cost reduction simultaneously, safeguarding profitability amid industry fluctuations.

3. Expand growth boundaries and activate growth potential. As a growth-oriented pharmaceutical company, Keyuan Pharmaceutical needs to balance consolidating traditional business and exploring new tracks: deepening domestic market penetration and terminal channels, while cautiously expanding into international markets through introducing high-quality products or technical collaborations. Additionally, it can leverage industry resources to explore supply chain synergies and create diversified growth points.

From Gao Chunpo to Wei Zhiguo, the management change at Keyuan Pharmaceutical reflects a strategic choice to adapt proactively to industry transformation. Short-term performance fluctuations do not alter the long-term growth logic. With a solid fundamental, a complementary new team, and a clear path to breakthrough, the company is equipped for high-quality development.

As a rising force in the pharmaceutical industry, Keyuan Pharmaceutical’s transformation and upgrading mirror the broader shift of China’s pharmaceutical sector from rapid growth to high-quality development. Under the waves of normalized procurement and intensified innovation-driven efforts, companies must root themselves in their core business, leverage management, adopt cyclical thinking to navigate fluctuations, and pursue long-termism to weather downturns and achieve sustainable progress.

This leadership change marks an important milestone in Keyuan Pharmaceutical’s development and a new starting point. Led by Wei Zhiguo and Li Yanbing, the company will pursue clearer strategies, more efficient management, and more stable operations to address short-term challenges, unlock long-term value, strengthen its advantages in specialty chemicals and raw materials, and move toward the goal of “better products, higher efficiency, broader boundaries,” continuing its journey of growth, transformation, and breakthrough.